Literature DB >> 21190982

Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais d'Etude des Tumeurs Endocrines.

V Rohmer1, G Vidal-Trecan, A Bourdelot, P Niccoli, A Murat, J L Wemeau, F Borson-Chazot, C Schvartz, A Tabarin, O Chabre, G Chabrier, P Caron, P Rodien, M Schlumberger, E Baudin.   

Abstract

BACKGROUND: In hereditary medullary thyroid carcinoma (HMTC), prophylactic surgery is the only curative option, which should be properly defined both in time and extent.
OBJECTIVES: To identify and characterize prognostic factors associated with disease-free survival (DFS) in children from HMTC families.
DESIGN: We conducted a retrospective analysis of a multi-center cohort of 170 patients below age 21 at surgery. Demographic, clinical, genetic, biological data [basal and pentagastrine-stimulated calcitonin (CT and CT/Pg, respectively)], and tumor node metastasis (TNM) status were collected. DFS was assessed based on basal CT levels. Kaplan-Meier curves, Cox regression, and logistic regression models were used to determine factors associated with DFS and TNM staging.
RESULTS: No patients with a preoperative basal CT <31 ng/ml had persistent or recurrent disease. Medullary thyroid carcinoma defined by a diameter ≥10 mm [hazard ratio (HR): 6.0; 95% confidence interval (95% CI): 1.8-19.8] and N1 status (HR: 20.8; 95% CI: 3.9-109.8) were independently associated with DFS. Class D genotype [odds ratio (OR): 48.5, 95% CI: 10.6-225.1], preoperative basal CT >30 ng/liter (OR: 43.4, 95% CI: 5.2-359.8), and age >10 (OR: 5.5, 95% CI: 1.4-21.8) were associated with medullary thyroid carcinoma ≥10 mm. No patient with a preoperative basal CT <31 ng/ml had a N1 status. Class D genotype (OR: 48.6, 95% CI: 8.6-274.1), and age >10 (OR: 4.6, 95% CI: 1.1-19.0) were associated with N1 status.
CONCLUSION: In HMTC patients, DFS is best predicted by TNM staging and preoperative basal CT level below 30 pg/ml. Basal CT, class D genotype, and age constitute key determinants to decide preoperatively timely surgery.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21190982     DOI: 10.1210/jc.2010-1234

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  22 in total

Review 1.  Management of hereditary medullary thyroid carcinoma.

Authors:  Theodora Pappa; Maria Alevizaki
Journal:  Endocrine       Date:  2016-02-02       Impact factor: 3.633

Review 2.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

3.  Role of preoperative basal calcitonin levels in the timing of prophylactic thyroidectomy in patients with germline RET mutations.

Authors:  Jean-Christophe Lifante; Claire Blanchard; Eric Mirallié; Albert David; Jean-Louis Peix
Journal:  World J Surg       Date:  2014-03       Impact factor: 3.352

4.  Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations.

Authors:  Thereasa A Rich; Lei Feng; Naifa Busaidy; Gilbert J Cote; Robert F Gagel; Mimi Hu; Camilo Jimenez; Jeffrey E Lee; Nancy Perrier; Steven I Sherman; Steven G Waguespack; Anita Ying; Elizabeth Grubbs
Journal:  Thyroid       Date:  2014-06-06       Impact factor: 6.568

Review 5.  Management of medullary thyroid carcinoma and MEN2 syndromes in childhood.

Authors:  Steven G Waguespack; Thereasa A Rich; Nancy D Perrier; Camilo Jimenez; Gilbert J Cote
Journal:  Nat Rev Endocrinol       Date:  2011-08-23       Impact factor: 43.330

6.  2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer.

Authors:  R Elisei; M Alevizaki; B Conte-Devolx; K Frank-Raue; V Leite; G R Williams
Journal:  Eur Thyroid J       Date:  2012-12-19

Review 7.  Paraganglioma and phaeochromocytoma: from genetics to personalized medicine.

Authors:  Judith Favier; Laurence Amar; Anne-Paule Gimenez-Roqueplo
Journal:  Nat Rev Endocrinol       Date:  2014-11-11       Impact factor: 43.330

8.  Ultrasonography should not guide the timing of thyroidectomy in pediatric patients diagnosed with multiple endocrine neoplasia syndrome 2A through genetic screening.

Authors:  Lilah F Morris; Steven G Waguespack; Beth S Edeiken-Monroe; Jeff E Lee; Thereasa A Rich; Anita K Ying; Carla L Warneke; Douglas B Evans; Nancy D Perrier; Elizabeth G Grubbs
Journal:  Ann Surg Oncol       Date:  2012-08-14       Impact factor: 5.344

9.  Timing and extent of thyroid surgery for gene carriers of hereditary C cell disease--a consensus statement of the European Society of Endocrine Surgeons (ESES).

Authors:  Bruno Niederle; Frédéric Sebag; Michael Brauckhoff
Journal:  Langenbecks Arch Surg       Date:  2013-12-03       Impact factor: 3.445

10.  Retrospective analysis of 140 cases of medullary thyroid carcinoma followed-up in a single institution.

Authors:  Joana Simões-Pereira; Maria João Bugalho; Edward Limbert; Valeriano Leite
Journal:  Oncol Lett       Date:  2016-04-20       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.